Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug

Laurie S. Conklin, Jesse M. Damsker, Eric P. Hoffman, William J. Jusko, Panteleimon D. Mavroudis, Benjamin D. Schwartz, Laurel J. Mengle-Gaw, Edward C. Smith, Jean K. Mah, Michela Guglieri, Yoram Nevo, Nancy Kuntz, Craig M McDonald, Mar Tulinius, Monique M. Ryan, Richard Webster, Diana Castro, Richard S. Finkel, Andrea L. Smith, Lauren P. MorgenrothAdrienne Arrieta, Maya Shimony, Mark Jaros, Phil Shale, John M. McCall, Yetrib Hathout, Kanneboyina Nagaraju, John van den Anker, Leanne M. Ward, Alexandra Ahmet, Michaelyn R. Cornish, Paula R. Clemens

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Fingerprint Dive into the research topics of 'Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug'. Together they form a unique fingerprint.

Medicine & Life Sciences